Two Sigma Investments
SABS icon

Two Sigma Investments’s SAB Biotherapeutics SABS Stock Holding History

Two Sigma Investments’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$694K Buy
+181,185
New +$722K ﹤0.01% 3503
2023
Q3 		– Sell
-2,509
Closed -$20.8K – 3179
2023
Q2 		$20.8K Buy
+2,509
New +$20.6K ﹤0.01% 2902

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments's SABS Position: Q1 2026 in Review

Two Sigma Investments opened a new position in SAB Biotherapeutics (SABS) in Q1 2026: 181,185 shares worth $694K. The stake represents ﹤0.01% of the portfolio and ranks #3503 among its holdings. This is a return to the name: Two Sigma Investments previously reported a position in SABS as recently as Q2 2023.

Two Sigma Investments first reported a position in SABS in Q2 2023 and has held it in 2 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Two Sigma Investments held 181,185 shares of SAB Biotherapeutics worth $694K as of Q1 2026.
  • SAB Biotherapeutics was a new Two Sigma Investments position in Q1 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #3503 holding.
  • Two Sigma Investments first reported a position in SAB Biotherapeutics in Q2 2023 and has held it in 2 quarters since.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.